Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NP-137 by Netris Pharma for Refractory Acute Myeloid Leukemia: Likelihood of Approval
NP-137 is under clinical development by Netris Pharma and currently in Phase II for Refractory Acute Myeloid Leukemia. According to...
NP-137 by Netris Pharma for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
NP-137 is under clinical development by Netris Pharma and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
NP-137 by Netris Pharma for Hepatocellular Carcinoma: Likelihood of Approval
NP-137 is under clinical development by Netris Pharma and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase...
NP-137 by Netris Pharma for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
NP-137 is under clinical development by Netris Pharma and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...